Elleste^™
(estradiol +/- norethisterone acetate)

The addition of a progestogen cyclically for at least 12 days per month/28 day cycle or continuous combined estrogen-progestogen therapy in non-hysterectomised women prevents the excessive risk of endometrial hyperplasia and carcinoma associated with estrogen-only HRT.^3-5

Elleste Solo^™ 2mg, Elleste Duet^™ 2mg and Elleste Duet^™ Conti 2mg can also be used as a second line agent to prevent osteoporosis in postmenopausal women.^2,4,5

Elleste Solo^™ contains estradiol 1mg or 2mg only and is suitable for hysterectomised women.^1,2

Whereas Elleste Duet^™ is a sequential combined therapy containing estradiol 1mg or 2mg with norethisterone acetate 1mg tablets for peri and post-menopausal women.^3,4

Elleste Duet^™ Conti is a continuous combined therapy of estradiol 2mg with norethisterone 1mg tablets for postmenopausal women.⁵

Elleste^™ is indicated for postmenopause and/or perimenopause women^1-5 with estrogen deficiency symptoms, such as hot flushes and night sweats. Additionally, menopausal women are at an increased risk of osteoporosis; Elleste Solo™ 2mg, Elleste Duet^™ 2mg and Elleste Duet^™ Conti 2mg are licensed for the prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis.^2,4,5

The side effects of Elleste^™ can range from headaches, nausea, bloating and diarrhoea to breast tenderness and irregular vaginal bleeding. Side effects may vary by product. For a full list of adverse effects, please consult the product SmPC.^1-5

Contraindications to prescribing Elleste^™ include: known, past or suspected breast cancer; known or suspected estrogen-dependent malignant tumours (e.g. endometrial cancer); undiagnosed genital bleeding; untreated endometrial hyperplasia; previous or current venous thromboembolism (deep venous thrombosis, pulmonary embolism); known thrombophilic disorders (e.g. protein C, protein S, or antithrombin deficiency); active or recent arterial thromboembolic disease (e.g. angina, myocardial infarction); acute liver disease, or a history of liver disease as long as liver function tests have failed to return to normal; hypersensitivity to the active substances or to any of the excipients listed; porphyria.

The contraindications may vary by product, please consult each products' individual SmPC for the list of contraindications.^1-5